<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532814</url>
  </required_header>
  <id_info>
    <org_study_id>20-002949</org_study_id>
    <secondary_id>R01DK045343</secondary_id>
    <nct_id>NCT04532814</nct_id>
  </id_info>
  <brief_title>Exercise-stimulated Muscle Glucose Uptake in Upper Body Obesity</brief_title>
  <official_title>Exercise-stimulated Muscle Glucose Uptake in Upper Body Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide the first integrated examination of the interaction&#xD;
      between muscle insulin action and exercise-stimulated muscle glucose uptake in obesity from&#xD;
      the whole body to the cellular/molecular level.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is aimed to determine whether obesity effects muscle glucose utilization during exercise.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal muscle glucose uptake</measure>
    <time_frame>1 hour</time_frame>
    <description>Is exercise induced skeletal muscle glucose uptake different in obese compared to lean adults</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Upper Body Obesity</condition>
  <arm_group>
    <arm_group_label>Lean</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Cycling 60% VO2 max</description>
    <arm_group_label>Lean</arm_group_label>
    <arm_group_label>Obese</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For the exercise studies of leg glucose uptake - &quot;insulin sensitive&quot; group:&#xD;
&#xD;
          -  Sedentary, normal weight, premenopausal women.&#xD;
&#xD;
          -  Sedentary, age-matched normal weight men.&#xD;
&#xD;
          -  Weight stable for two (2) months prior to study.&#xD;
&#xD;
          -  Willing to provide written, informed consent.&#xD;
&#xD;
          -  For the exercise studies of leg glucose uptake - &quot;insulin resistant&quot; group:&#xD;
&#xD;
        For the exercise studies of leg glucose uptake - &quot;insulin resistant&quot; group:&#xD;
&#xD;
          -  Upper body obese (UBO) premenopausal women.&#xD;
&#xD;
          -  Age-matched upper body obese (UBO) men.&#xD;
&#xD;
          -  Weight stable for two (2) months prior to study.&#xD;
&#xD;
          -  Willing to provide written, informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 or &gt; 55 years (premenopausal women and age-matched men).&#xD;
&#xD;
          -  Use of glucose-lowering agents.&#xD;
&#xD;
          -  For female subjects: positive pregnancy test at the time of enrollment or study&#xD;
&#xD;
          -  History of prior upper abdominal surgery such as adjustable gastric banding,&#xD;
             pyloroplasty and vagotomy.&#xD;
&#xD;
          -  Active systemic illness or malignancy.&#xD;
&#xD;
          -  Symptomatic macrovascular or microvascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pamela Reich</last_name>
    <phone>507-255-6062</phone>
    <email>reich.Pamela@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael D Jensen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael D. Jensen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

